Cholangiocarcinoma

William C. Palmer; Denise M. Harnois

doi:10.1007/978-3-319-13614-1_23

Cholangiocarcinoma

William C. Palmer, Denise M. Harnois

Gastroenterology and Hepatology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Cholangiocarcinoma (CCA), an uncommon biliary adenocarcinoma, can be divided into intrahepatic and extrahepatic types. Intrahepatic CCA (IH-CCA) comprises approximately 25 % of all CCAs, and can be characterized as peripheral mass-forming or central periductal infiltrating tumors. Most patients do not possess known risk factors, but a strong association with cirrhosis has been documented. The clinical presentation of IH-CCA can be nonspecific even in the late stages of the disease. Management combines surgical resection, systemic chemotherapy, and targeted radiation therapy. Surgically unresectable disease is incurable with current treatment options. Enrollment in clinical trials and referral to tertiary centers are recommended for patients with unresectable or recurrent disease.

Original language	English (US)
Title of host publication	Complications of Cirrhosis
Subtitle of host publication	Evaluation and Management
Publisher	Springer International Publishing
Pages	219-227
Number of pages	9
ISBN (Electronic)	9783319136141
ISBN (Print)	9783319136134
DOIs	https://doi.org/10.1007/978-3-319-13614-1_23
State	Published - Jan 1 2015

Keywords

Bile duct cancer
Cirrhosis
Liver cancer
Liver transplantation

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-319-13614-1_23

Cite this

@inbook{342ac71f8ef142bc8c800a6a85c8f1f6,

title = "Cholangiocarcinoma",

abstract = "Cholangiocarcinoma (CCA), an uncommon biliary adenocarcinoma, can be divided into intrahepatic and extrahepatic types. Intrahepatic CCA (IH-CCA) comprises approximately 25 % of all CCAs, and can be characterized as peripheral mass-forming or central periductal infiltrating tumors. Most patients do not possess known risk factors, but a strong association with cirrhosis has been documented. The clinical presentation of IH-CCA can be nonspecific even in the late stages of the disease. Management combines surgical resection, systemic chemotherapy, and targeted radiation therapy. Surgically unresectable disease is incurable with current treatment options. Enrollment in clinical trials and referral to tertiary centers are recommended for patients with unresectable or recurrent disease.",

keywords = "Bile duct cancer, Cirrhosis, Liver cancer, Liver transplantation",

author = "Palmer, {William C.} and Harnois, {Denise M.}",

note = "Publisher Copyright: {\textcopyright} Springer International Publishing Switzerland 2015.",

year = "2015",

month = jan,

day = "1",

doi = "10.1007/978-3-319-13614-1_23",

language = "English (US)",

isbn = "9783319136134",

pages = "219--227",

booktitle = "Complications of Cirrhosis",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Cholangiocarcinoma

AU - Palmer, William C.

AU - Harnois, Denise M.

N1 - Publisher Copyright: © Springer International Publishing Switzerland 2015.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Cholangiocarcinoma (CCA), an uncommon biliary adenocarcinoma, can be divided into intrahepatic and extrahepatic types. Intrahepatic CCA (IH-CCA) comprises approximately 25 % of all CCAs, and can be characterized as peripheral mass-forming or central periductal infiltrating tumors. Most patients do not possess known risk factors, but a strong association with cirrhosis has been documented. The clinical presentation of IH-CCA can be nonspecific even in the late stages of the disease. Management combines surgical resection, systemic chemotherapy, and targeted radiation therapy. Surgically unresectable disease is incurable with current treatment options. Enrollment in clinical trials and referral to tertiary centers are recommended for patients with unresectable or recurrent disease.

AB - Cholangiocarcinoma (CCA), an uncommon biliary adenocarcinoma, can be divided into intrahepatic and extrahepatic types. Intrahepatic CCA (IH-CCA) comprises approximately 25 % of all CCAs, and can be characterized as peripheral mass-forming or central periductal infiltrating tumors. Most patients do not possess known risk factors, but a strong association with cirrhosis has been documented. The clinical presentation of IH-CCA can be nonspecific even in the late stages of the disease. Management combines surgical resection, systemic chemotherapy, and targeted radiation therapy. Surgically unresectable disease is incurable with current treatment options. Enrollment in clinical trials and referral to tertiary centers are recommended for patients with unresectable or recurrent disease.

KW - Bile duct cancer

KW - Cirrhosis

KW - Liver cancer

KW - Liver transplantation

UR - http://www.scopus.com/inward/record.url?scp=84944602722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944602722&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-13614-1_23

DO - 10.1007/978-3-319-13614-1_23

M3 - Chapter

AN - SCOPUS:84944602722

SN - 9783319136134

SP - 219

EP - 227

BT - Complications of Cirrhosis

PB - Springer International Publishing

ER -

Cholangiocarcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this